Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Receivables - Net (2016 - 2017)

Historic Receivables - Net for Usana Health Sciences (USNA) over the last 5 years, with Q3 2017 value amounting to $6.9 million.

  • Usana Health Sciences' Receivables - Net fell 689.98% to $6.9 million in Q3 2017 from the same period last year, while for Jul 2017 it was $6.9 million, marking a year-over-year decrease of 689.98%. This contributed to the annual value of $6.9 million for FY2016, which is 1765.2% down from last year.
  • Per Usana Health Sciences' latest filing, its Receivables - Net stood at $6.9 million for Q3 2017, which was down 689.98% from $6.8 million recorded in Q2 2017.
  • Usana Health Sciences' Receivables - Net's 5-year high stood at $9.0 million during Q3 2015, with a 5-year trough of $4.9 million in Q4 2013.
  • In the last 5 years, Usana Health Sciences' Receivables - Net had a median value of $7.4 million in 2016 and averaged $7.5 million.
  • In the last 5 years, Usana Health Sciences' Receivables - Net skyrocketed by 7237.96% in 2015 and then crashed by 1872.93% in 2016.
  • Usana Health Sciences' Receivables - Net (Quarter) stood at $4.9 million in 2013, then soared by 48.91% to $7.4 million in 2014, then grew by 18.7% to $8.7 million in 2015, then dropped by 21.39% to $6.9 million in 2016, then rose by 0.01% to $6.9 million in 2017.
  • Its Receivables - Net was $6.9 million in Q3 2017, compared to $6.8 million in Q2 2017 and $6.9 million in Q4 2016.